Bateman–Horn conjecture

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Drug development, FM, PK, Food, Celecoxib, Polaris Sales Agreement, Conference call, ET, Outline, Bateman–Horn conjecture, Fibromyalgia, Webcast, Conditional sentence, Research, FDA, Credit, Therapy, Valaciclovir, Conference, Safety, Pharmaceutical industry

ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • ET -
    ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • Research and development expenses for the second quarter of 2023 were $0.6 million, compared to $2.4 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $0.9 million, compared to $1.3 million for the second quarter of 2022.
  • Virios Therapeutics management will host a webcast and conference call on August 10, 2023, at 8:30 a.m.

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Pharmaceutical, Health, Clinical Trials, Valaciclovir, Pain, Company, FM, BHC, Long COVID, Conditional sentence, Research, Nasdaq, Center of excellence, Webcast, Patient, Simplex, Therapy, Functional somatic syndrome, Bateman–Horn conjecture, Clinical trial, PASC, COVID-19, Investor, Fibromyalgia, FDA, Accounting, Center, Conference, Anxiety, Short bowel syndrome, Attention, Celecoxib, Famciclovir, Chronic fatigue syndrome, Diagnosis, Fatigue, CEO, Sleep, Pharmaceutical industry

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced financial results for the first quarter ended March 31, 2022.
  • Research and development expenses for the first quarter of 2022 were $2.8 million, compared to $1.7 million for the first quarter of 2021.
  • General and administrative expenses for the first quarter of 2022 were $1.2 million, compared to $1.4 million for the first quarter of 2021.
  • Virios Therapeutics management will host a webcast and conference call on May 12, 2022, at 8:30 a.m.